Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Xarelto┬«
NICE TA: 335
Indication: Preventing adverse outcomes after acute management of acute coronary syndrome (NICE TA335)
Disease category: Cardiovascular system
Commissioning responsibility: CCG
PbR excluded: No


Rivaroxaban with aspirin alone, or with aspirin plus clopidogrel, is recommended as possible treatment for adults who have had acute coronary syndrome with raised cardiac biomarkers. A decision on continuation of treatment should be taken no later than 12 months after starting treatment. Extension of treatment beyond 12 months should be done on an individual patient basis because experience up to 24 months is limited. The licensed dose for rivaroxaban post ACS is 2.5mg twice daily. Prescribers should be aware that this dose does not provide VTE level anticoagulation.


LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

NICE TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG